Who are Cholbam's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Kybella, Prelone, prednisolon, Kybella, Cholbam, Doxycycline and tauroursodeoxycholic acid.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/cholic-acid.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-14 · How we verify

Cholbam — Competitive Intelligence Brief

Cholbam (CHOLIC ACID) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Bile Acid [EPC]. Area: Metabolic.

marketed Bile Acid [EPC] G-protein coupled bile acid receptor 1 Metabolic Small molecule Live · refreshed every 30 min

Target snapshot

Cholbam (CHOLIC ACID) — Mirum. Cholbam works by binding to the G-protein coupled bile acid receptor 1, which helps regulate bile acid levels in the body.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Cholbam TARGET	CHOLIC ACID	Mirum	marketed	Bile Acid [EPC]	G-protein coupled bile acid receptor 1	2015-01-01
Kybella	DEOXYCHOLIC ACID	AbbVie	marketed	Cytolytic Agent [EPC]	G-protein coupled bile acid receptor 1	2015-01-01
Prelone	prednisolone	Generic (originally Schering)	marketed	Glucocorticoid (corticosteroid)	Annexin A1, Corticosteroid-binding globulin, G-protein coupled bile acid receptor 1	1955-01-01
prednisolon	prednisolon	Hannover Medical School	marketed		Annexin A1, Corticosteroid-binding globulin, G-protein coupled bile acid receptor 1
Kybella	Kybella	Massachusetts General Hospital	marketed		G-protein coupled bile acid receptor 1, fMet-Leu-Phe receptor, Bile acid receptor
Cholbam	Cholbam	Mirum Pharmaceuticals, Inc.	marketed		G-protein coupled bile acid receptor 1, Bile acid receptor
Doxycycline and tauroursodeoxycholic acid	Doxycycline and tauroursodeoxycholic acid	Fondazione IRCCS Policlinico San Matteo di Pavia	phase 3	Combination therapy (antibiotic + bile acid derivative)	Matrix metalloproteinases, FXR (farnesoid X receptor), TGR5 (G-protein coupled bile acid receptor 1)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Bile Acid [EPC] class)

· 1 drug in this class
AbbVie · 1 drug in this class
Mirum · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Cholbam — Competitive Intelligence Brief. https://druglandscape.com/ci/cholic-acid. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab